

Special Issue

Infectious Diseases: Antibodies and Vaccines

Message from the Guest Editors

Dear Colleagues, In the ongoing battle against human infectious diseases, antibodies and vaccines stand as powerful weapons, providing both preventive and therapeutic functions. This Special Issue serves as a comprehensive exploration of the latest advancements and insights in the field of immunology, focusing on the roles of antibodies and vaccines in combating infectious pathogens. This Special Issue presents a diverse array of research, ranging from fundamental discoveries in antibody biology to cutting-edge developments in vaccine design and delivery. Through a multidisciplinary lens, our topic delves into various aspects of immunity, including the generation of neutralizing antibodies, the mechanisms of vaccine-induced protection, and the challenges posed by emerging infectious threats. Key topics addressed in this Special Issue are as follows:

- Novel vaccine platforms and adjuvants for enhancing immune responses;
- Harnessing monoclonal antibodies for therapeutic intervention against infectious agents;
- Immune correlates of protection and their implications for vaccine efficacy;
- Strategies for enhancing vaccine uptake.

Guest Editors

Dr. Huibin Lv

Department of Biochemistry, University of Illinois at Urbana Champaign, Urbana, IL 61801, USA

Dr. Yupeng Feng

Institute for Immunity, Transplantation and Infection, Stanford University, Stanford, CA 94305, USA

Deadline for manuscript submissions

closed (31 December 2024)



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/162461

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.5
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition and Behavior, University College
Roosevelt, 4331 CB Middelburg, The Netherlands

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).